

Table S1. PRA of 11 patients who had positive for anti-HLA antibody before administration of BNT162b2 (number 1 to 11) and one patient who developed anti-HLA after BNT162b2 vaccination (number 12). None of them developed de novo DSA after BNT162b2 vaccination.

No.	Group	Age, years	Sex	Transplantation	Duration after transplant, years	Before		After	
						BNT162b2		BNT162b2	
						PRA, %	DSA	PRA, %	DSA
1	MPA sparing	49	M	LKT	4.75	20	No	20	No
2	Standard	44	F	DKT	7.25	41	No	41	No
3	Standard	31	F	DKT	1.08	17	No	43	No
4	Standard	44	F	DKT	3.16	18	No	39	No
5	Standard	42	F	DKT	5.59	79	Yes	79	Yes
6	Standard	39	F	LKT	1.91	71	Yes	49	Yes
7	Standard	73	M	DKT	18.86	91	Yes	91	Yes
8	Standard	63	M	DKT	8.16	54	No	66	No
9	Standard	49	F	LKT	4.91	40	Yes	29	Yes
10	Standard	39	F	DKT	1.33	88	No	88	No
11	Standard	63	F	DKT	0.99	2	No	0	No
12	Standard	56	F	LKT	4.75	0	No	9	No
Mean ± SD, %						43.42 ± 32.89		46.17 ± 29.87	
						P = 0.479			

DKT, deceased donor kidney transplantation; DSA, donor-specific anti-HLA antibody; F, female; LKT, living donor kidney transplantation; M, male; PRA, panel-reactive antibody.

Table S2. Characteristics of patients who developed COVID-19 infection within 3 months after vaccination. Two (5.1%) of 39 patients of the MPA-sparing group and 7 (6.1%) of 115 patients of the standard group had COVID-19 infection within 3 months of follow up.

No.	Group	Age, years	Sex	Transplantation	Duration after transplant, years	Cause of ESRD	Anti-SARS-CoV-2 S antibody		Clinical of COVID-19 infection
							Post-two doses of ChAdOx-1, BAU/m L	Post-BNT162b2, BAU/m L	
1	MPA sparing	35	M	DKT	3.33	DN	567.69	12 939.30	URI
2	MPA sparing	42	F	LKT	1.33	Hypertension	Negative	17.78	URI
3	Standard	44	F	DKT	3.16	Unknown	Negative	Negative	URI
4	Standard	48	F	DKT	5.02	CGN	95.00	887.45	URI
5	Standard	56	F	LKT	4.75	DN	Negative	Negative	Pneumonia
6	Standard	68	M	DKT	4.50	Hypertension	Negative	25.69	URI
7	Standard	51	F	LKT	4.91	Hypertension	50.84	3987.65	URI

BAU, binding antibody unit; CGN, chronic glomerulonephritis; COVID-19, coronavirus disease 2019; DKT, deceased donor kidney transplantation; DN, diabetic nephropathy; DSA, donor-specific anti-HLA antibody; ESRD, end-stage renal disease; F, female; LKT, living donor kidney transplantation; M, male; MPA, mycophenolic acid; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; URI, upper respiratory tract infection.